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ABSTRACT
Objective: Comparing Health-Related Quality of Life (HRQoL) scores in patients with 
chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible 
factors related to HRQoL. Method: HRQoL was assessed using the Short Form 36 and 
Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 
and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated 
interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and 
telaprevir. Results: The reduction of HRQoL was greater in patients receiving triple 
therapy compared to those treated with two drugs, the most critical time is at 12 weeks in 
both groups. After removal of telaprevir, the triple therapy group significantly improved 
their HRQoL scores. Anxiety and depression before treatment, employment status and 
race are significantly related to diminished HRQoL. Conclusion: Patients undergoing 
double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir 
chooses a more significant decrease.
DESCRIPTORS
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INTRODUCTION
Approximately 1.5% of the world population is chroni-
cally infected by the Hepatitis C Virus (HCV)(1-3). In addi-
tion to its high prevalence, chronic Hepatitis C is a leading 
cause of liver cirrhosis, hepatocellular carcinoma and liver 
transplant indications worldwide(4-5).
Recently in Brazil, new drugs have become available for 
treating chronic hepatitis C, namely direct action antivirals 
such as telaprevir (TVR) and boceprevir (BOC). They are 
recommended for patients with genotype 1 and advanced 
fibrosis. If, on the one hand there has been a 30% increase 
in sustained virological response (SVR) rates(6), on the other, 
the frequency and severity of adverse events have signifi-
cantly increased(6-8).
Lately, Health-Related Quality of Life (HRQoL) 
has gained prominence as a tool to assess the impact of 
chronic diseases and their treatments on the perception 
of health and patient well-being(4,9-10). For this purpose, 
Short Form 36 (SF-36), a generic instrument, and Chronic 
Liver Disease Questionnaire (CLDQ), which is specifically 
for HRQoL analysis in patients with chronic liver disease, 
have been used(11).
Studies have shown that untreated patients with chronic 
hepatitis C and those undergoing antiviral therapy with pe-
gylated interferon (PEG-IFN) and ribavirin present sig-
nificant diminished quality of life indices(4,9-10,12-13). How-
ever, in Brazil there is the perspective of providing more 
effective drugs and with fewer adverse events, and triple 
therapy with telaprevir will possibly remain as a therapeu-
tic option. Therefore, the aim of this study was to assess 
HRQoL scores in patients with chronic hepatitis C un-
dergoing double (PEG-IFN and RBV) and triple therapy 
(PEG-IFN, RBV and TVR) and to identify possible factors 
involved in the perception of HRQoL.
METHOD
A prospective cohort observational study which includ-
ed patients aged between 18 and 75 years and who had a 
diagnosis of chronic hepatitis C established by the presence 
of HCV in RNA serum carried out by the Polymerase Chain 
Reaction – Real Time (RT-PCR) technique with antiviral 
therapy indication as per the recommendations of the Clin-
ical and Therapeutic Protocol Guidelines for Viral Hepa-
titis C of the Brazilian Ministry of Health, 2013, Decree 
number 221 from July,13th 2011 – SVS/MS(14). Genotyping 
was performed by the same procedure and both tests were 
performed at Fundação Ezequiel Dias, Belo Horizonte. All 
patients were on regular follow-up in the Reference Center 
for Viral Hepatitis at the University Hospital Gastroenter-
ology Service of the Universidade Federal de Juiz de Fora 
(HU-UFJF), in the period from March 2012 to July 2014. 
All medications are offered free by the Unified Brazilian 
Health System (SUS).
Patients under 18 or over 75 years of age, those infected 
with the human immunodeficiency virus (HIV), Hepati-
tis B virus (HBV) and chronic kidney disease (creatinine 
greater than 1.5 mg/dL) were excluded.
According to the protocol of the Brazilian Ministry of 
Health (2013), patients infected with genotype 1 with grade 
3 or 4 liver fibrosis should receive triple therapy, and double 
therapy for the remaining others. Double therapy consists 
in the use of PEG-IFN alpha 2a (180 micrograms) or 2b 
(1.5 micrograms/kg of body weight) along with ribavirin 
1000 mg (<75 kg) and 1250mg/day (≥75kg), once a week. 
Treatment duration is 24 weeks for genotype 2 or 3, and 48 
weeks for genotype 1. In addition to PEG-IFN and RBV, 
the triple therapy group received telaprevir (TPV) at a dose 
of 1.125 mg twice day for the first 12 weeks, followed by 
double therapy until the end of treatment(14). All patients 
were followed up to 16 weeks of treatment, since the aim 
of the study was to determine the influence of telaprevir on 
HRQoL indexes, and what differs between both groups up 
to the 12th week of treatment is the presence of telaprevir. 
To check the behavior of HRQoL scores after the with-
drawal of telaprevir, a new evaluation of HRQoL was per-
formed 4 weeks after its suspension (at 16 weeks). Clinical 
follow-ups were conducted according to the CRHV routine 
of the HU-UFJF. According to therapeutic guidelines of 
the Ministry of Health, new determinations of HCV viral 
load were conducted at weeks 4 and 12. A negative HCV 
viral load at week 4 was considered as a rapid virological 
response (RVR), and for patients on triple therapy, rapid 
virological response extended to negative HCV viral load 
at weeks 4 and 12. The criteria for therapy discontinua-
tion were based on the recommendations of the Ministry 
of Health protocol.
Prior to the start of therapy, sociodemographic vari-
ables (gender, age, race, marital status, employment status, 
education level, smoking, alcohol consumption), laboratory 
variables (genotype, HCV viral load, hemoglobin levels), 
and histological information (degree of liver fibrosis accord-
ing to the METAVIR Scale, 1996) were collected through 
clinical consultation carried out by the assistant team and 
an interview conducted by the researcher.
At baseline, and at weeks 4, 12 and 16 of treatment, anx-
iety and depression were screened through the application 
of the Hospital Anxiety and Depression Scale (HADS) us-
ing the translated and validated version for the Brazilian 
population. HADS consists of 14 items, seven for anxiety 
identification (HADS-A) and seven for depression symp-
toms (HADS-D), and it only takes into account psycho-
logical symptoms. A depression episode was considered for 
patients with HADS-D > 8 and HADS-A > 8(15).
In order to assess HRQoL, all study participants re-
sponded to the Short Form 36 (SF-36) and to the Chronic 
Liver Diseases Questionnaire (CLDQ). The questionnaires 
were applied in Portuguese at baseline and at weeks 4, 12 
and 16 of therapy. Assistant staff was blinded to the results 
of applied scores. SF-36 is a generic instrument universally 
used to assess HRQoL(16-17). SF-36 questionnaire consists of 
11 questions and 36 items covering eight domains: physi-
cal functioning, physical aspects, bodily pain, general health 
perceptions, vitality, social functioning, emotional function-
ing and mental health. For data analysis, the eight domains 
were grouped into two major components: Physical Com-
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ponent Summary (PCS) and Mental Component Summa-
ry (MCS). The individual received a score in each domain, 
ranging from 0 to 100, with 0 being the worst and 100 the 
best(17). CLDQ is specific to assess HRQoL in patients with 
chronic liver disease. It consists of 29 items divided into 
six domains: abdominal symptoms, fatigue, systemic symp-
toms, activity, emotional function and worry. The scores cal-
culated for each domain ranged from 1 to 7. Higher scores 
indicated a minimum frequency of symptoms, and hence a 
better HRQoL. Total score is calculated based on the aver-
age of all 29 items(18).
Statistical analysis was performed using SPSS 16.0 
(SPSS, Chicago, IL). Non-parametric variables were ex-
pressed as median and those with normal distribution as 
mean ± standard deviation (SD). Descriptive statistics of 
all the relevant variables for the two groups were calculated. 
For data analysis, HRQoL indexes were compared among 
double and triple therapy groups. Independent t-test was 
used to compare the difference of means at each moment 
of therapy. Multivariate linear regression model was used to 
identify factors independently associated to HRQoL. Re-
gression analysis of the variables in the correlation analysis 
that had p<0.15 were included. For comparison, the level of 
significance was P<0.05.
The study protocol was approved by the Eth-
ics Committee Research of HU-UFJF, Brazil, CAAE 
01601512.6.0000.5133.
RESULTS
32 patients were included, being 17 treated with double 
therapy (INF + RIB) and 15 with triple therapy (INF + 
RIB + TEL). Most patients were female (59%) and 25% 
were married. There was a predominance of genotype 1 
(75%) and liver cirrhosis was present in 34% of patients. 
The comparative analysis between the two groups showed 
no difference in terms of sociodemographic characteristics, 
such as gender, race, marital status, education, professional 
status, smoking or alcohol consumption, which shows ho-
mogeneity between groups.
HRQoL accoRding SF-36
At baseline, the average of Physical Component Sum-
mary (PCS) from SF-36 was similar in the double and 
triple therapy groups (51.5 ± 8.4 vs. 53.8 ± 6.0; p=0.413). 
After the start of treatment, HRQoL scores declined in 
both groups, but in the triple therapy group the reduction 
was more pronounced. At week 12, the PCS average was 
worse in patients treated with three drugs (27.7 ± 4.06 vs. 
37.6 ± 8.23; p <0.001). At week 16, four weeks after tela-
previr discontinuation, there was a recovery of PCS scores, 
however, they still remained lower in the triple therapy 
group (35.0 ± 3.66 vs. 40.8 ± 9.33; p=0.026). Compar-
ing the differences (decrease) between the contents of the 
PCS before treatment and at week 12 (-26.03 ± 8.11 vs. 
– 11.88 ± 10.65; p<0.001) there was a greater reduction 
observed in the triple therapy patients (Figure 1). Among 
the PCS domains, physical functioning (PF) was the most 
compromised in the triple compared to double therapy, at 
weeks 4 (34.66 ± 2.85 vs. 64.17 ± 2.39; p=0.003) and week 
12 (17.06 ± 1.60 vs. 59.52 ± 2.64; p<0.001). At week 16, 
four weeks after the withdrawal of telaprevir, physical func-
tioning (PF) became similar between the groups (55.82 ± 
2.58 vs. 45.53 ± 1.03; p=0.144).
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Figure 1 – Physical Component Summary (PCS) during the 16 
weeks of treatment, SF-36 – Juiz de Fora, MG, Brazil, 2014.
At baseline, the Mental Components Summary (MCS) 
of the SF-36 were similar in both groups (60.1 ± 3.80 vs. 
55.1 ± 9.11; p=0.067). At weeks 4 and 12, MCS scores were 
similar, but at week 16, the average MCS was lower in pa-
tients undergoing triple therapy (36.2 ± 5.46 vs. 46.4 ± 1.19; 
p = 0.004) (Figure 2). Among MCS domains, vitality (VIT) 
was the most affected. The average for the VIT domain was 
significantly lower in patients on triple therapy at weeks 4 
(26.93 ± 1.04 vs. 52.64 ± 3.09; p=0.004) and 12 (23.66 ± 
1.90 vs. 51.76 ± 2.76; p = 0.002). At week 16, four weeks 
after the withdrawal of telaprevir, the VIT scores were simi-
lar in both groups (46.53 ± 9.97 vs. 53.82 ± 2.94; p=0.348). 
The difference (increase) in VIT rates at week 16 compared 
to week 12 was significantly higher in patients treated with 
three drugs (22.86 ± 2.44 vs. 2.95 ± 2.26; p=0.015).
Week of treatment
M
C
S
65
60
55
50
45
40
35
30
0 4 12 16
p = 0.005
Double Therapy
Triple Therapy
p = 0.051p = 0.013
p = 0.067
SF-36: Mental Component Summary
Figure 2 – Mental Component Summary (MCS) during the 16 
weeks of treatment, SF-36 – Juiz de Fora, MG, Brazil, 2014.
When analyzing the domains individually, week 12 
showed the worst scores of HRQoL. Physical function-
ing (PF) (17.06 ± 1.60 vs. 59.52 ± 2.64; p<0.001), physi-
cal aspects (PA) (0.00 ± 0.00 vs. 30.82 ± 3.7; p=0.003), 
bodily pain (31.96 ± 2.83 vs. 61.17 ± 2.84; p=0.007), vital-
ity (VIT) (23.66 ± 1.90 vs. 51.76 ± 2.76; p=0.002), social 
functioning (SF) (37.53 ± 2.840 vs. 73.79 ± 3.43; p=0.003), 
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emotional functioning (EF) (21.66 ± 3.88 vs. 56. 70 ± 4.95; 
p=0.033) and mental health (MH) (42.16 ± 2.11 vs. 61.58 
± 2.66; p=0.031) were significantly worse in the triple 
therapy group.
HRQoL accoRding to cLdQ
At baseline, total CLDQ score was similar in both 
groups (6.30 ± 0.55 vs. 6.20 ± 0.86; p=0.69). However, dur-
ing treatment scores were significantly worse in the triple 
therapy group at 4 weeks (5.29 ± 1.02 vs. 3.96 ± 0.81; p 
<0.001) and 12 weeks (4.97 ± 1.00 vs. 3.40 ± 1.19; p<0.001). 
At week 16, four weeks after discontinuation of telaprevir, 
the scores remained worse in the triple therapy group (5.28 
± 1.08 vs. 4.25 ± 0.89; p=0.007) (Figure 3).
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Figure 3 – CLDQ – TOTAL during the 16 weeks of treatment – Juiz 
de Fora, MG, Brazil, 2014.
Fatigue (FAT) was the CLDQ domain most affected in 
patients on triple therapy at weeks 4 (2.77 ± 1.19 vs. 4.78 
± 1.39; p<0.001), 12 (2.20 ± 0.83 vs. 4.54 ± 1.81; p<0.001) 
and 16 (3.53 ± 1.12 vs. 4.64 ± 1.63; p=0.038). In compar-
ing the differences (decrease) between the total scores of 
the CLDQ obtained before treatment vs. week 12, the re-
duction observed was greater in the triple treatment group 
(-2.07 ± 1.22 vs. – 1.33 ± 1.31, p=0.003).
Week 12 of treatment was the worst with respect to 
CLDQ scores. Abdominal symptoms (AS) (3.83 ± 2.21 vs. 
5.67 ± 1.58; p = 0.011), fatigue (FAT) (2.20 ± 0.83 vs. 4.54 
± 1.81, p <0.001), systemic symptoms (SS) (2.75 ± 0.90 vs. 
4.59 ± 1.19; p <0.001), activity (ACT) (2.86 ± 1.63 vs. 4.73 
± 1.49; p = 0.002), emotional function (EF) (3.10 ± 1.80 vs. 
4.96 ± 1.59; p = 0.004), worry (WOR) (5.16 ± 1.60 vs. 6.47 
± 0.79; p = 0.009) and total (TT) (4.97 ± 1.00 vs. 3.40 ± 
1.19; p <0.001) domains were significantly lower in patients 
on triple therapy.
identiFying HRQoL pRedictoRS – SF 36 and cLdQ
With predictors of quality of life, it became evident 
that triple therapy was independently associated with lower 
HRQoL by both the SF-36 and the CLDQ. Regarding 
the SPC, only the triple treatment was associated with di-
minished HRQoL (β= – 0.680, p<0.001). The presence of 
anxiety (β= – 0.602, p<0.001) and depression (β= – 0.571, 
p=0.001) before treatment and employment status (β= 
0.425, p=0.0015) was associated with the SMC. Accord-
ing to CLDQ, anxiety (β= – 0.592, p<0.001), depression 
(β= – 0.614, p<0.001), triple therapy (β= – 0.593, p<0.001), 
race (β= 0.360, p=0.043) and employment status (β= 0.356, 
p=0.045) were predictors of HRQoL. The decline of 
HRQoL scores according to the CLDQ questionnaire was 
associated with a higher chance of obtaining rapid virologi-
cal response (RVR) (β= 0.388, p=0.028), being higher in the 
triple therapy group (93.3% vs. 47.1%; p=0.003).
DISCUSSION
In recent years, the treatment of chronic hepatitis C has 
substantially evolved with the introduction of more effec-
tive drugs with fewer adverse events. In Brazil, the standard 
treatment for patients with HCV genotype 1 and advanced 
fibrosis is triple therapy with protease telaprevir and bo-
ceprevir inhibitors. In addition to efficacy and safety, quality 
of life measures are important parameters to be determined 
during antiviral therapy and increasingly valued for select-
ing the most appropriate treatments.
It is known that chronic hepatitis C causes a decline in 
HRQoL indexes, even without advanced liver disease(19-20). 
In a systematic review including 15 studies, patients with 
chronic hepatitis C without signs of advanced disease de-
clined in HRQoL of the SF-36 in both physical and men-
tal component summary(21). As expected in patients with 
liver cirrhosis, the HRQoL reduction is even greater(22-23). 
Until recently, the standard therapy of chronic hepatitis C 
was a PEG-IFN and ribavirin combination. However, this 
treatment is associated with a number of adverse effects 
such as fatigue, influenza-like symptoms (flu-like), anemia, 
and neuropsychiatric disorders that affect quality of life and 
eventually lead to discontinuation of therapy. A study of 
1860 patients with chronic hepatitis C treated with PEG-
IFN and ribavirin showed a reduction in quality of life 
scores from SF-36(24). Studies evaluating the quality of life 
in patients undergoing double therapy are scarce and triple 
therapy even scarcer.
In our study, it was demonstrated that patients treated 
with three drugs (telaprevir) had a greater reduction in 
quality of life indexes. According to the SF-36, the most 
significant decrease was in the PCS, specifically in func-
tional capacity. It was noted that week 12 was the most 
critical, and at week 16, four weeks after the withdrawal 
of telaprevir, there was a recovery of HRQoL, but it still 
remained lower in comparison to patients on double ther-
apy. This fact clearly shows that telaprevir is responsible 
for these findings. Although this study has the limitation 
of not having evaluated the association between anemia 
and HRQoL, it is possible that the lower HRQoL rates 
observed in patients on triple therapy can be justified by 
its presence. The treatment of patients with double thera-
py is associated with the development of dose-dependent 
hemolytic anemia induced by ribavirin. The addition of 
telaprevir increases the incidence of anemia, as was shown 
in one study in which 30% and 15% of patients treated 
with triple therapy (PEG-IFN + ribavirin + telaprevir) 
and double therapy developed anemia, respectively(25). In a 
study published evaluating the safety of telaprevir in 1782 
941www.ee.usp.br/reeusp Rev Esc Enferm USP · 2015; 49(6):937-943
Fagundes RN, Ferreira LEVVC, Pace FHL
patients with advanced liver fibrosis, anemia was present in 
931 (59%) patients and 157 (10%) patients required blood 
transfusions(26). Another study reported that 90% of 2084 
patients treated with triple therapy in the US experienced 
adverse events, requiring some intervention and 39% of 
patients discontinued therapy prematurely(27). It is possible 
that such events have also contributed to the diminished 
HRQoL observed in this study.
Regarding MCS, the reduction was only higher in pa-
tients undergoing triple therapy at week 16. Adverse events 
on neuropsychological functions during antiviral therapy 
are mainly related to Interferon, and the addition of tela-
previr might not enhance such effects, which may explain 
this finding.
According to CLDQ, the behavior of quality of life 
scores was very similar to that observed with the SF-36, 
showing good concordance between the questionnaires. It 
was worse in patients on triple therapy at weeks 4 and 12 
with partial recovery at week 16, but remained worse at 
this point when compared to patients on double therapy. In 
both questionnaires week 12 was critical, during which we 
observed the lowest levels of HRQoL. Similarly, other stud-
ies showed lower levels of HRQoL at week 12 of treatment 
with double therapy(24,28).
During antiviral therapy, it is important to identify 
factors associated with deterioration of HRQoL early 
on so that interventions can be made with the objective 
of maintaining treatment, thereby avoiding its premature 
interruption and failure. Treatment with three drugs was 
independently associated to a diminished HRQoL, which 
motivates the search for new drugs, which fortunately are to 
be made available soon in Brazil. However, it is possible that 
telaprevir may still remain as a therapeutic option in Brazil. 
In our study, the presence of anxiety and depression prior to 
treatment, employment status and race were associated with 
HRQoL. Thus, routine screening of psychiatric disorders 
appear to be recommended.
An important predictor of SVR is the negativity of 
the virus in the fourth week of treatment, corresponding 
to rapid virological response. As expected, RVR occurred 
more often in the triple therapy group (93.3% vs. 47.1%; 
p=0.003) and, interestingly, a relationship between worse 
HRQoL according to CLDQ and RVR was demonstrated. 
Studies have shown that the occurrence of significant ad-
verse events is related to a higher chance of SVR, and that 
there is an association between lower levels of hemoglobin 
and sustained virological response among patients with 
chronic hepatitis C treated with PEG-IFN and ribavirin(29).
The small sample size can be highlighted as the main 
limitation of the study, justified by a restrictive inclusion 
criteria for patients on antiviral therapy with protease in-
hibitors. Another limitation is that the treatment of chronic 
hepatitis C with telaprevir will soon be replaced by new 
direct action antiviral agents, but the understanding of the 
evolution of antiviral therapy in its various aspects such as 
efficacy, tolerance and quality of life remains relevant.
In Brazil, the approval of the second generation Direct 
Action Antivirals (DAA) Daclatasvir, Simeprevir and So-
fosbuvir are expected in 2015. These drugs are highly ef-
ficient, have a low incidence of adverse events, and a more 
convenient dosage, which enables shorter treatment and 
eligibility of a larger number of patients(30). Furthermore, 
in a recent study it was shown that the use of Sofosbuvir 
caused a minimal impact on HRQoL in patients undergo-
ing antiviral therapy, demonstrating its good tolerance(5).
CONCLUSION
According to SF-36 and CLDQ, patients undergoing 
double and triple therapy have reduced HRQoL indexes, 
but the addition of telaprevir confers a more significant de-
crease of HRQoL. In Brazil, the incorporation of new drugs 
for the treatment of patients with chronic hepatitis C with 
less impact on quality of life is pressing.
RESUMO
Objetivo: Comparar os escores de Qualidade de Vida Relacionada à Saúde (QVRS) em pacientes com hepatite crônica C submetidos 
à terapia antiviral dupla e tripla e analisar os possíveis fatores relacionados à QVRS. Método: A QVRS foi avaliada utilizando o Short 
Form 36 e o Chronic Liver Disease Questionnaire, que foram aplicados antes e nas semanas 4, 12 e 16 de tratamento, em 32 pacientes 
divididos em 2 grupos: terapia dupla com interferon peguilado (IFN-PEG) e ribavirina e tripla com IFN-PEG, ribavirina e telaprevir. 
Resultados: A redução da QVRS foi maior em pacientes em terapia tripla quando comparados àqueles tratados com duas drogas, sendo 
o momento mais crítico a 12ª semana em ambos os grupos. Após a retirada do telaprevir, o grupo terapia tripla melhorou de modo 
significativo os escores de QVRS. Ansiedade e depressão no pré-tratamento, status empregatício e raça se mostraram relacionados à 
redução da QVRS. Conclusão: Pacientes submetidos à terapia dupla e tripla apresentam redução dos índices de QVRS, mas a adição do 
telaprevir confere uma queda mais expressiva.
DESCRITORES
Hepatite C; Qualidade de Vida; Terapia Combinada; Ribavirina; Interferons; Inibidores de Proteases.
RESUMEN
Objetivo: Comparar los puntajes de Calidad de Vida Relacionada con la Salud (CVRS) en pacientes con hepatitis C crónica sometidos 
a la terapia antiviral doble y triple y analizar los posibles factores relacionados con la CVRS. Método: La CVRS fue evaluada utilizando 
el Short Form 36 y el Chronic Liver Disease Questionnaire, que fueron aplicados antes y en las semanas 4, 12 y 16 de tratamiento, en 
32 pacientes divididos en 2 grupos: terapia doble con interferón pegilado (IFN-PEG) y ribavirina, y triple con IFN-PEG, ribavirina 
y telaprevir. Resultados: La reducción de la CVRS fue mayor en pacientes en terapia triple cuando comparados con los tratados con 
dos drogas, siendo el momento más crítico la 12ª semana en ambos grupos. Después de la retirada del telaprevir, el grupo de terapia 
triple mejoró de modo significativo los puntajes de CVRS. Ansiedad y depresión en el pre tratamiento, situación de empleo y raza se 
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mostraron relacionados con la reducción de la CVRS. Conclusión: Pacientes sometidos a la terapia doble y triple presentan reducción 
de los índices de CVRS, pero la adición del telaprevir les proporciona una caída más expresiva.
DESCRIPTORES
Hepatitis C; Calidad de Vida; Terapia Combinada; Ribavirina; El Interferones; Inhibidores de Proteasas.
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